CNS Pharmaceuticals

CNSP · NASDAQ

$4.99−$0.01 (−0.20%)TodayMarket closed · Oct 20, 6:50 PM ET

Prev close $5.00

About CNSP

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 8 full-time employees. The company went IPO on 2019-11-08. The firm's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The firm's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.

Employees: 5
Headquarters: Houston, Texas
Listed: Nov 8, 2019
Sector: Health Care
Industry: Pharmaceuticals
Website: cnspharma.com

Leadership

CNS Pharmaceuticals executives
Name	Title	Since	Age
Faith Charles	—	—	63
Rami Levin	—	2026	56
Steve O'Loughlin	—	—	41
Donald Picker	—	—	79
Lynne Kelley	—	—	63
Bettina Cockroft	—	—	57
Carl Evans	—	—	77
Jerzy Gumulka	—	—	75
Jeffry Keyes	—	—	51
Amy Mahery	—	—	48

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

CNS Pharmaceuticals suppliers and customers
Company	Relationship	Country	Correlation
Reata Pharmaceuticals A RETA	Supplier and customer	US	0.95
WPD Pharmaceuticals WBIO	Supplier and customer	CA	—
Animal Life Sciences, Inc.	Supplier and customer	US	—
University of Texas M.D. Anderson Cancer Center	Supplier and customer	US	—

Similar companies

Companies in the same industry as CNS Pharmaceuticals

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.